Table 2.

Effectiveness of nivolumab treatment during the 2-year follow-up period

	Overall (n = 256)	2-year survivors (n = 62)
Evaluable patients	223 (87.1)	60 (23.4)
BOR
Complete response	3 (1.3)	3 (5.0)
Partial response	33 (14.8)	25 (41.7)
Stable disease	60 (26.9)	21 (35.0)
Progressive disease	127 (57.0)	11 (18.3)
ORR	36 (16.1) 95% CI 11.6–21.6	28 (46.7) 95% CI 33.7–60.0
DCR	96 (43.0) 95% CI 36.5–49.8	49 (81.7) 95% CI 69.6–90.5

Data are n (%)

Response rates were calculated in evaluable patients

BOR best overall response, CI confidence interval, DCR disease control rate, ORR objective response rate